Global Pulmonary Hypertension Drug Market is expected to grow at a CAGR of 7.2% during the forecast period, to reach USD 2.5 billion by 2030 from USD 1.6 billion in 2018. The market is driven by factors such as increasing prevalence of pulmonary hypertension and growing awareness about the disease among patients and physicians, which are expected to drive the market growth over the next few years.
The global pulmonary hypertension drug market is segmented on the basis of type into prostacyclin and prostacyclin analogs, endothelin receptor antagonists, phosphodiesterase 5 inhibitors, soluble guanylate cyclase stimulators; on application into earlstage drug candidates (phase I & phase II), latstage drug candidates (phase III & registration phase); and region into North America, Latin America, Europe, Asia Pacific and Middle East & Africa.
Some Of The Growth Factors Of This Market:
- Increasing prevalence of pulmonary hypertension in developed countries and emerging economies such as China, India, Brazil, and Russia is expected to drive the growth of the global Pulmonary Hypertension Drug market over the next few years.
- The increasing number of new product launches by major players in this industry is also expected to fuel the growth of this market over the next few years.
- Increasing awareness about pulmonary hypertension among patients and healthcare providers will also drive demand for these drugs over time.
- The high cost associated with these drugs will be a restraining factor for this market.
Industry Growth Insights published a new data on “Pulmonary Hypertension Drug Market”. The research report is titled “Pulmonary Hypertension Drug Market research by Types (Prostacyclin and Prostacyclin Analogs, Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors, Soluble Guanylate Cyclase Stimulators), By Applications (Early-stage Drug Candidates (Phase I & Phase II), Late-stage Drug Candidates (Phase III & Registration Phase)), By Players/Companies GlaxoSmithKline plc, Novartis AG, Merck & Co., Inc., Abbott Laboratories, Boehringer Ingelheim GmbH, AstraZeneca plc, F. Hoffmann-La Roche AG, Teva Pharmaceutical Industries Ltd., Vectura Group plc, Pfizer Inc.”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Pulmonary Hypertension Drug Market Research Report
By Type
Prostacyclin and Prostacyclin Analogs, Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors, Soluble Guanylate Cyclase Stimulators
By Application
Early-stage Drug Candidates (Phase I & Phase II), Late-stage Drug Candidates (Phase III & Registration Phase)
By Companies
GlaxoSmithKline plc, Novartis AG, Merck & Co., Inc., Abbott Laboratories, Boehringer Ingelheim GmbH, AstraZeneca plc, F. Hoffmann-La Roche AG, Teva Pharmaceutical Industries Ltd., Vectura Group plc, Pfizer Inc.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
234
Number of Tables & Figures
164
Customization Available
Yes, the report can be customized as per your need.
Global Pulmonary Hypertension Drug Market Report Segments:
The global Pulmonary Hypertension Drug market is segmented on the basis of:
Types
Prostacyclin and Prostacyclin Analogs, Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors, Soluble Guanylate Cyclase Stimulators
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Early-stage Drug Candidates (Phase I & Phase II), Late-stage Drug Candidates (Phase III & Registration Phase)
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- GlaxoSmithKline plc
- Novartis AG
- Merck & Co., Inc.
- Abbott Laboratories
- Boehringer Ingelheim GmbH
- AstraZeneca plc
- F. Hoffmann-La Roche AG
- Teva Pharmaceutical Industries Ltd.
- Vectura Group plc
- Pfizer Inc.
Highlights of The Pulmonary Hypertension Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Prostacyclin and Prostacyclin Analogs
- Endothelin Receptor Antagonists
- Phosphodiesterase-5 Inhibitors
- Soluble Guanylate Cyclase Stimulators
- By Application:
- Early-stage Drug Candidates (Phase I & Phase II)
- Late-stage Drug Candidates (Phase III & Registration Phase)
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Pulmonary Hypertension Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Pulmonary hypertension (PH) is a medical condition in which the pressure inside the lungs rises to levels that can cause difficulty breathing. The most common type of PH is chronic obstructive pulmonary disease (COPD), which includes conditions such as bronchitis and emphysema. COPD often leads to PH, because the narrowed airways make it difficult for oxygen to reach the lungs.nnDrugs used to treat PH include beta blockers, ACE inhibitors, and calcium channel blockers. These drugs work by reducing blood pressure or preventing heart muscle from contracting too hard.
Some of the key players operating in the pulmonary hypertension drug market are GlaxoSmithKline plc, Novartis AG, Merck & Co., Inc., Abbott Laboratories, Boehringer Ingelheim GmbH, AstraZeneca plc, F. Hoffmann-La Roche AG, Teva Pharmaceutical Industries Ltd., Vectura Group plc, Pfizer Inc..
The pulmonary hypertension drug market is expected to register a CAGR of 7.2%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Pulmonary Hypertension Drug Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Pulmonary Hypertension Drug Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Pulmonary Hypertension Drug Market - Supply Chain
4.5. Global Pulmonary Hypertension Drug Market Forecast
4.5.1. Pulmonary Hypertension Drug Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Pulmonary Hypertension Drug Market Size (000 Units) and Y-o-Y Growth
4.5.3. Pulmonary Hypertension Drug Market Absolute $ Opportunity
5. Global Pulmonary Hypertension Drug Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Pulmonary Hypertension Drug Market Size and Volume Forecast by Type
5.3.1. Prostacyclin and Prostacyclin Analogs
5.3.2. Endothelin Receptor Antagonists
5.3.3. Phosphodiesterase-5 Inhibitors
5.3.4. Soluble Guanylate Cyclase Stimulators
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Pulmonary Hypertension Drug Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Pulmonary Hypertension Drug Market Size and Volume Forecast by Application
6.3.1. Early-stage Drug Candidates (Phase I & Phase II)
6.3.2. Late-stage Drug Candidates (Phase III & Registration Phase)
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Pulmonary Hypertension Drug Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Pulmonary Hypertension Drug Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Pulmonary Hypertension Drug Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Pulmonary Hypertension Drug Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Pulmonary Hypertension Drug Demand Share Forecast, 2019-2026
9. North America Pulmonary Hypertension Drug Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Pulmonary Hypertension Drug Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Pulmonary Hypertension Drug Market Size and Volume Forecast by Application
9.4.1. Early-stage Drug Candidates (Phase I & Phase II)
9.4.2. Late-stage Drug Candidates (Phase III & Registration Phase)
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Pulmonary Hypertension Drug Market Size and Volume Forecast by Type
9.7.1. Prostacyclin and Prostacyclin Analogs
9.7.2. Endothelin Receptor Antagonists
9.7.3. Phosphodiesterase-5 Inhibitors
9.7.4. Soluble Guanylate Cyclase Stimulators
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Pulmonary Hypertension Drug Demand Share Forecast, 2019-2026
10. Latin America Pulmonary Hypertension Drug Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Pulmonary Hypertension Drug Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Pulmonary Hypertension Drug Market Size and Volume Forecast by Application
10.4.1. Early-stage Drug Candidates (Phase I & Phase II)
10.4.2. Late-stage Drug Candidates (Phase III & Registration Phase)
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Pulmonary Hypertension Drug Market Size and Volume Forecast by Type
10.7.1. Prostacyclin and Prostacyclin Analogs
10.7.2. Endothelin Receptor Antagonists
10.7.3. Phosphodiesterase-5 Inhibitors
10.7.4. Soluble Guanylate Cyclase Stimulators
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Pulmonary Hypertension Drug Demand Share Forecast, 2019-2026
11. Europe Pulmonary Hypertension Drug Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Pulmonary Hypertension Drug Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Pulmonary Hypertension Drug Market Size and Volume Forecast by Application
11.4.1. Early-stage Drug Candidates (Phase I & Phase II)
11.4.2. Late-stage Drug Candidates (Phase III & Registration Phase)
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Pulmonary Hypertension Drug Market Size and Volume Forecast by Type
11.7.1. Prostacyclin and Prostacyclin Analogs
11.7.2. Endothelin Receptor Antagonists
11.7.3. Phosphodiesterase-5 Inhibitors
11.7.4. Soluble Guanylate Cyclase Stimulators
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Pulmonary Hypertension Drug Demand Share, 2019-2026
12. Asia Pacific Pulmonary Hypertension Drug Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Pulmonary Hypertension Drug Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Pulmonary Hypertension Drug Market Size and Volume Forecast by Application
12.4.1. Early-stage Drug Candidates (Phase I & Phase II)
12.4.2. Late-stage Drug Candidates (Phase III & Registration Phase)
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Pulmonary Hypertension Drug Market Size and Volume Forecast by Type
12.7.1. Prostacyclin and Prostacyclin Analogs
12.7.2. Endothelin Receptor Antagonists
12.7.3. Phosphodiesterase-5 Inhibitors
12.7.4. Soluble Guanylate Cyclase Stimulators
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Pulmonary Hypertension Drug Demand Share, 2019-2026
13. Middle East & Africa Pulmonary Hypertension Drug Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Pulmonary Hypertension Drug Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Pulmonary Hypertension Drug Market Size and Volume Forecast by Application
13.4.1. Early-stage Drug Candidates (Phase I & Phase II)
13.4.2. Late-stage Drug Candidates (Phase III & Registration Phase)
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Pulmonary Hypertension Drug Market Size and Volume Forecast by Type
13.7.1. Prostacyclin and Prostacyclin Analogs
13.7.2. Endothelin Receptor Antagonists
13.7.3. Phosphodiesterase-5 Inhibitors
13.7.4. Soluble Guanylate Cyclase Stimulators
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Pulmonary Hypertension Drug Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Pulmonary Hypertension Drug Market: Market Share Analysis
14.2. Pulmonary Hypertension Drug Distributors and Customers
14.3. Pulmonary Hypertension Drug Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. GlaxoSmithKline plc
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Novartis AG
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Merck & Co., Inc.
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Abbott Laboratories
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Boehringer Ingelheim GmbH
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. AstraZeneca plc
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. F. Hoffmann-La Roche AG
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Teva Pharmaceutical Industries Ltd.
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Vectura Group plc
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Pfizer Inc.
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
